FI102383B1 - Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi - Google Patents

Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi

Info

Publication number
FI102383B1
FI102383B1 FI900783A FI900783A FI102383B1 FI 102383 B1 FI102383 B1 FI 102383B1 FI 900783 A FI900783 A FI 900783A FI 900783 A FI900783 A FI 900783A FI 102383 B1 FI102383 B1 FI 102383B1
Authority
FI
Finland
Prior art keywords
modified
plasmid
domain
producing
protein containing
Prior art date
Application number
FI900783A
Other languages
English (en)
Swedish (sv)
Other versions
FI102383B (fi
FI900783A0 (fi
Inventor
Allen Oliff
Gwynneth M Edwards
Deborah D Jones
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI900783A0 publication Critical patent/FI900783A0/fi
Application granted granted Critical
Publication of FI102383B publication Critical patent/FI102383B/fi
Publication of FI102383B1 publication Critical patent/FI102383B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI900783A 1989-02-17 1990-02-16 Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi FI102383B1 (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31254089A 1989-02-17 1989-02-17
US31254089 1989-02-17
US38909289A 1989-08-03 1989-08-03
US38909289 1989-08-03
US44918789A 1989-12-21 1989-12-21
US44918789 1989-12-21

Publications (3)

Publication Number Publication Date
FI900783A0 FI900783A0 (fi) 1990-02-16
FI102383B FI102383B (fi) 1998-11-30
FI102383B1 true FI102383B1 (fi) 1998-11-30

Family

ID=27405603

Family Applications (1)

Application Number Title Priority Date Filing Date
FI900783A FI102383B1 (fi) 1989-02-17 1990-02-16 Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi

Country Status (18)

Country Link
EP (1) EP0383599B1 (fi)
JP (2) JPH07106159B2 (fi)
KR (1) KR0169729B1 (fi)
AT (1) ATE133993T1 (fi)
AU (1) AU617039B2 (fi)
CA (1) CA2010256C (fi)
CY (1) CY1987A (fi)
DE (1) DE69025211T2 (fi)
DK (1) DK0383599T3 (fi)
ES (1) ES2085329T3 (fi)
FI (1) FI102383B1 (fi)
GR (1) GR3019836T3 (fi)
HK (1) HK15597A (fi)
IE (1) IE71934B1 (fi)
IL (1) IL93425A (fi)
NO (1) NO300595B1 (fi)
NZ (1) NZ232564A (fi)
PT (1) PT93178B (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
AU641392B2 (en) * 1989-04-21 1993-09-23 Protein Design Laboratories, Inc. Recombinant antibody-toxin fusion protein
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
EP0965597A4 (en) * 1996-12-27 2003-01-08 Mochida Pharm Co Ltd CELL MEMBRANE EFFECTIVE DRUGS
JP2001525669A (ja) * 1997-05-12 2001-12-11 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 細胞遊走の阻害のための方法および構築物
GB0008802D0 (en) * 2000-04-10 2000-05-31 Univ London Molecule
JP4940136B2 (ja) * 2004-06-28 2012-05-30 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド キメラタンパク質およびその使用
CN105766069B (zh) 2013-11-20 2019-04-16 株式会社村田制作所 多层布线基板及具备该多层布线基板的探针卡
JP6795813B2 (ja) * 2015-10-05 2020-12-02 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
AU641392B2 (en) * 1989-04-21 1993-09-23 Protein Design Laboratories, Inc. Recombinant antibody-toxin fusion protein

Also Published As

Publication number Publication date
CY1987A (en) 1997-09-05
DK0383599T3 (da) 1996-08-05
FI102383B (fi) 1998-11-30
EP0383599A3 (en) 1991-03-27
CA2010256C (en) 2000-07-25
KR0169729B1 (ko) 1999-01-15
KR900012626A (ko) 1990-09-01
HK15597A (en) 1997-02-14
DE69025211T2 (de) 1996-09-19
JPH02276590A (ja) 1990-11-13
EP0383599B1 (en) 1996-02-07
CA2010256A1 (en) 1990-08-17
EP0383599A2 (en) 1990-08-22
IE71934B1 (en) 1997-03-12
NO300595B1 (no) 1997-06-23
ES2085329T3 (es) 1996-06-01
DE69025211D1 (de) 1996-03-21
JPH07278200A (ja) 1995-10-24
FI900783A0 (fi) 1990-02-16
JP2510846B2 (ja) 1996-06-26
NO900758D0 (no) 1990-02-16
JPH07106159B2 (ja) 1995-11-15
ATE133993T1 (de) 1996-02-15
NO900758L (no) 1990-08-20
AU617039B2 (en) 1991-11-14
GR3019836T3 (en) 1996-08-31
IL93425A0 (en) 1990-11-29
PT93178B (pt) 1996-04-30
NZ232564A (en) 1992-08-26
AU4994690A (en) 1990-08-23
IL93425A (en) 1999-08-17
PT93178A (pt) 1990-08-31
IE900587L (en) 1990-08-17

Similar Documents

Publication Publication Date Title
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
ES2060594T3 (es) Proceso para purificar proteinas recombinantes y uso de productos de las mismas.
DE3686654D1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
ES2087323T3 (es) Metodo para producir peptidos exentos de cisteina.
FI102383B1 (fi) Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi
DE69034254D1 (de) A-pdgf-rezeptor und dessen verwendung
ATE164838T1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
ES2109225T3 (es) Anticuerpos, su produccion y uso.
KR890008166A (ko) 융합 단백질의 선택적 분해 방법
ATE103973T1 (de) Gamma-atriales, natriuretisches polypeptid erkennende monoklonale antikoerper, solche antikoerper produzierende hybridome und deren herstellung und verwendung.
DE59005082D1 (de) Antikörper gegen hochkonservierte Aminosäuresequenzen von immunogenen Substanzen, Verfahren zur Herstellung dieser Antikörper, sowie deren Verwendung in Immunoassays.

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: MERCK & CO., INC.